Early-stage breast cancer treatment decisions, particularly for hormone receptor-positive, HER2-negative tumors, rely on accurate risk stratification to balance the benefits of adjuvant chemotherapy against potential overtreatment. Here, ERBB2 is linked to breast carcinoma.